Clinical trials: ACS
ACS (Acute Coronary Syndrome), HF - Heart Failure
A Clinical Study on the Effect of Cardiopulmonary Function and Quality of Life in Patients With Acute Coronary Syndrome Complicated by Heart Failure by "Lying-Sitting-Standing" Sequential Baduanjin
This study investigates the effects of a sequential "lying-sitting-standing" Baduanjin intervention on patients with acute coronary syndrome complicated by heart failure.
- Trial name
- NCT07486791
- Testing
- standard treatment and routine rehabilitation nursing guidance, "Lying-Sitting-Standing" Sequential Baduanjin
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Xiling Qi
Acute Coronary Syndrome
Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of ACS
Antiplatelet agents are cornerstones for management of ischemic heart disease. For patients suffering from acute coronary syndrome (heart attack), treatment with aspirin and ticagrelor are typically given for one year after index…
- Trial name
- FMD_ACS (NCT03881943)
- Testing
- Ticagrelor 60 mg, Aspirin 100 MG Oral Tablet, Enteric Coated
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The University of Hong Kong
Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR)
Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy
Study Purpose Coronary heart disease (CAD) is a leading global cause of death, with Acute Coronary Syndrome (ACS) as its acute and life-threatening subtype.
- Conditions
- Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR), Coronary Artery Disease (CAD)
- Trial name
- NCT07354828
- Where
- China
- Volunteers
- 3,500 people
- Sponsor
- Shenyang Northern Hospital
Acute Coronary Syndrome (ACS)
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in…
- Trial name
- NCT07625306
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals
ACS - Acute Coronary Syndrome
Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics
The study is a multicenter, Phase 1, open-label, sequential, adaptive, single dose, PK/PD study in subjects with moderate and severe RI and healthy volunteers (HV).
- Trial name
- NCT05323136
- Testing
- MT1002 for Injection
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD)
Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy
This study evaluates whether fexuprazan is effective in preventing upper gastrointestinal bleeding and related upper gastrointestinal clinical events in high bleeding risk patients who require dual antiplatelet therapy after…
- Trial name
- SAINT-FEXUDAPT (NCT07479056)
- Testing
- Fexuprazan 40mg, Lansoprazole 30mg
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- SUK MIN SEO
Myocardial Infarction (MI), ST-Elevation Myocardial Infarction
Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction
Drug-eluting stent (DES)-based primary percutaneous intervention (pPCI) has been established as the standard of care for patients presenting with ST-segment elevation myocardial infarction (STEMI), having demonstrated superiority…
- Conditions
- Myocardial Infarction (MI), ST-Elevation Myocardial Infarction, STEMI, STEMI (STE-ACS)
- Trial name
- DCB-STEMI (NCT07436429)
- Testing
- Drug-Coated Balloon
- Where
- Austria
- Volunteers
- 300 people
- Sponsor
- Medical University of Vienna
Acute Coronary Syndrome
Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile.
- Trial name
- dal-GenE (NCT02525939)
- Testing
- dalcetrapib
- Where
- 557 sites in United States, Argentina and 30 more
- Volunteers
- 6,147 people
- Sponsor
- DalCor Pharmaceuticals
Acute Coronary Syndrome
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)
The study is going to compare two different doses of aspirin for the treatment of heart disease in combination with the anticlotting medication ticagrelor.
- Trial name
- WILLOW-ACS (NCT02741817)
- Testing
- Aspirin
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Acute Compartment Syndrome
The Research About the ACS After Femoropopliteal Arterial Injuries
Crural Compartment syndrome is a well-known sequela after femoropopliteal arterial injuries in the lower extremity, particularly when there has been a long period of ischemia,need for ligation of a major vein, or when there is…
- Trial name
- NCT05030259
- Testing
- fasciotomy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Hebei Medical University Third Hospital
Acute Coronary Syndrome
Short and Long Term Outcomes of Acute Coronary Syndrome in Patients With Non Obstructive Coronary Atherosclerosis
The purpose of the study is to assess short and long term outcomes of acute coronary syndrome in patients with non obstructive coronary atherosclerosis, to optimize the algorithm for diagnosis and to evaluate its effectiveness
- Trial name
- NOCA (NCT02655718)
- Testing
- Patients with ACS, MRI
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Russian Academy of Medical Sciences
Acute Coronary Syndrome, Myocardial Infarction
Point of Care (POC) Biomarkers of Ischemia
Acute coronary syndrome is defined as myocardial infarction or ischemia as evidenced by significant coronary artery disease on cardiac catheterization/revascularization or reversible defect seen on stress test.
- Trial name
- NCT02039882
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Acute Coronary Syndrome
Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial
Dual antiplatelet therapy with aspirin and Clopidogrel for at least one year is essential in patients following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) with drug eluting stent(s.
- Trial name
- RESET GENE (NCT01465828)
- Testing
- Clopidogrel, prasugrel
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Gennaro Sardella
Acute Coronary Syndrome
Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects
The aim of the current study is to evaluate whether treatment with high doses of simvastatin can reduce coagulation activation in patients with acute coronary syndromes and if ezetimibe in conjunction with simvastatin may affect…
- Trial name
- NCT00725829
- Testing
- simvastatin, ezetimibe
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Jagiellonian University
Acute Coronary Syndrome, ACS (Acute Coronary Syndrome)
Evaluation of Remnant Cholesterol Levels and Monocyte-to-HDL-cholesterol Ratio as Predictors of Coronary Artery Disease Severity in Patients With Acute Coronary Syndrome
1. Evaluation of serum level of remnant cholesterol and monocyte/HDL ratio as predictors of severity of coronary artery disease in patients with acute coronary syndrome. 2.
- Conditions
- Acute Coronary Syndrome, ACS (Acute Coronary Syndrome), Monocyte to HDL Cholesterol Ratio, STEMI
- Trial name
- NCT06757777
- Volunteers
- 54 people
- Sponsor
- Assiut University
Myocardial Infarction (MI), Acute Coronary Syndrome (ACS)
Ticino Artificial InTelligence integrAtioN for Occlusion Myocardial Infarction
The goal of this clinical trial is to evaluate whether an artificial intelligence (AI)-based ECG interpretation tool improves the early diagnosis and treatment of occlusion myocardial infarction (OMI) in adults presenting with…
- Trial name
- TITAN-OMI (NCT07077057)
- Testing
- AI-assisted ECG interpretation (PMcardio)
- Where
- Switzerland
- Volunteers
- 500 people
- Sponsor
- Cardiocentro Ticino
Acute Coronary Syndromes (ACS), NSTEMI - Non-ST-Segment Elevation Myocardial Infarction
The CORE - μFR Clinical Trial
Acute coronary syndromes (ACS) are frequently associated with multivessel coronary artery disease (CAD), and current guidelines recommend complete revascularization beyond the culprit lesion.
- Conditions
- Acute Coronary Syndromes (ACS), NSTEMI - Non-ST-Segment Elevation Myocardial Infarction, STEMI - ST Elevation Myocardial Infarction, Multivessel Coronary Artery Disease
- Trial name
- NCT07598565
- Testing
- Angiography-guided PCI, μFR based-PCI
- Where
- Italy
- Volunteers
- 350 people
- Sponsor
- University of Roma La Sapienza
Non ST Segment Elevation Acute Coronary Syndrome
Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI
It is designed to test the hypothesis that high loading dose(360mg) ticagrelor versus conventional loading dose(180mg) will result in a higher inhibition of platelet aggregation(IPA) without increasing the bleeding events.
- Trial name
- NCT01962428
- Testing
- ticagrelor
- Where
- 2 sites in China
- Volunteers
- 250 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Non ST Segment Elevation Acute Coronary Syndrome, Coronary Artery Disease
Non-IRA Functional Evaluation With AccuFFRangio in NSTE-ACS
This is a prospective, single-center clinical trial. AccuFFRangio (ArteryFlow Technology Co., Ltd., Hangzhou, China) is a novel method for evaluating the functional significance of coronary stenosis by computing the pressure in…
- Conditions
- Non ST Segment Elevation Acute Coronary Syndrome, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- NCT05202041
- Testing
- AccuFFRangio-guided strategy, Angiography-guided strategy
- Volunteers
- 500 people
- Sponsor
- Wuhan Asia Heart Hospital
Acute Coronary Syndromes
Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry
The primary objective of the UPSTREAM Registry is to address the data gap regarding the course of NSTEMI (Non-ST-Elevation Myocardial Infarction)between ED (Emergency Department) arrival and diagnostic angiography in detail, by…
- Trial name
- NCT02271022
- Testing
- Non-Interventional Study
- Where
- 55 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca